Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2020 Dec 1;130(12):6225-6227.
doi: 10.1172/JCI143292.

Caring for patients in a new pandemic: the necessity and challenges of observational research

David L Thomas
Comment

Caring for patients in a new pandemic: the necessity and challenges of observational research

David L Thomas. J Clin Invest. .

Abstract

Individuals with coronavirus disease 2019 (COVID-19) can develop pneumonia and a severe inflammatory response with excessive cytokine release known as the cytokine storm. The JAK inhibitor baricitinib, used to treat rheumatoid arthritis, reduces inflammation by modifying the cytokine pathway. In this issue of the JCI, Bronte, Ugel, and colleagues performed an observational longitudinal study to evaluate the use of baricitinib in 20 patients with COVID-19. The treated patients showed reduced levels of plasma IL-6, TNF, IL-1β, and phosphorylated STAT3 as well as swift lymphocyte restoration. Notably, these patients had a dramatically favorable clinical outcome. While bias can plague uncontrolled research, this study has biological credibility and warrants randomized, controlled studies.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: The author has declared that no conflict of interest exists.

Comment on

  • Baricitinib restrains the immune dysregulation in patients with severe COVID-19.
    Bronte V, Ugel S, Tinazzi E, Vella A, De Sanctis F, Canè S, Batani V, Trovato R, Fiore A, Petrova V, Hofer F, Barouni RM, Musiu C, Caligola S, Pinton L, Torroni L, Polati E, Donadello K, Friso S, Pizzolo F, Iezzi M, Facciotti F, Pelicci PG, Righetti D, Bazzoni P, Rampudda M, Comel A, Mosaner W, Lunardi C, Olivieri O. Bronte V, et al. J Clin Invest. 2020 Dec 1;130(12):6409-6416. doi: 10.1172/JCI141772. J Clin Invest. 2020. PMID: 32809969 Free PMC article. Clinical Trial.

References

    1. Bronte V, et al. Baricitinib restrains the immune dysregulation in patients with severe COVID-19. J Clin Invest. 2020;130(12):6409–6416. - PMC - PubMed
    1. Kitahata MM, et al. Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med. 2009;360(18):1815–1826. doi: 10.1056/NEJMoa0807252. - DOI - PMC - PubMed
    1. BLundgren JD, et al. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 2015;373(9):795–807. doi: 10.1056/NEJMoa1506816. - DOI - PMC - PubMed
    1. Gao J, Tian Z, Yang X. Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends. 2020;14(1):72–73. doi: 10.5582/bst.2020.01047. - DOI - PubMed
    1. Sarma P, et al. Virological and clinical cure in COVID-19 patients treated with hydroxychloroquine: a systematic review meta-analysis. J Med Virol. 2020;92(7):776–785. doi: 10.1002/jmv.25898. - DOI - PMC - PubMed